Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders

Revista Brasileira de Psiquiatria

Volumn 39, Issue 3, 2017, Pages 195-200

  Guloksuz, Selin Aktan ^a   Abali, Osman ^b   Cetin, Esin Aktas ^b   Gazioglu, Sema Bilgic ^b   Deniz, Gunnur ^b   Yildirim, Abdurrahman ^c   Kawikova, Ivana ^d   Guloksuz, Sinan ^d,e   Leckman, James F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

^c MEMORIAL HOSPITAL   (Turkey)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Autism; Cytokine; Glia; Inflammation; S100B; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; PROTEIN S100B; S100B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AUTISM; BLOOD; BODY MASS; CHILD; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX;

AUTISM SPECTRUM DISORDER; BIOMARKERS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERLEUKINS; MALE; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85027526554     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2015-1843     Document Type: Article

References (36)

1. Mitchell RH, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry. 2014;53:274-96.
2. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol. 2013;8:900-20.
3. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2012;26: 383-92.
4. McDougle CJ, Landino SM, Vahabzadeh A, O’Rourke J, Zurcher NR, Finger BC, et al. Toward an immune-mediated subtype of autism spectrum disorder. Brain Res. 2015;1617:72-92.
5. Rodriguez JI, Kern JK. Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol. 2011;7:205-13.
6. Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, et al. Microglial activation in young adults with autismspectrum disorder. JAMA Psychiatry. 2013;70:49-58.
7. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010;68:368-76.
8. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Altered T cell responses in children with autism. Brain Behav Immun. 2011;25:840-9.
9. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011;25:40-5.
10. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001;120:170-9.
11. Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res. 2013;24:491-501.
12. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology. 2002;45:1-6.
13. El-Ansary A, Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. J Neuroinflammation. 2012;9:265.
14. Suzuki K, Matsuzaki H, Iwata K, Kameno Y, Shimmura C, Kawai S, et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PloS One. 2011;6:e20470.
15. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin-17A in children with autism. J Neuroinflammation. 2012;9:158.
16. Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:187-90.
17. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793:1008-22.
18. Rothermundt M, Ahn JN, Jorgens S. S100B in schizophrenia: an update. Gen Physiol Biophys. 2009;28 Spec No Focus: F76-81.
19. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets. 2013;14:1237-48.
20. Edwards MM, Robinson SR. TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer’s disease. J Neural Transm (Vienna). 2006;113:1709-15.
21. Al-Ayadhi LY, Mostafa GA. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. J Neuroinflammation. 2012;9:54.
22. Egger G, Roetzer KM, Noor A, Lionel AC, Mahmood H, Schwarz-braun T, et al. Identification of risk genes for autism spectrum disorder through copy number variation analysis in Austrian families. Neurogenetics. 2014;15:117-27.
23. Schopler E, Reichler RJ, Rochen Renner B. The Childhood Autism Rating Scale (CARS).Los Angeles: Western Psychological Services; 1988.
24. Goldberg WA, Osann K, Filipek PA, Laulhere T, Jarvis K, Modahl C, et al. Language and other regression: assessment and timing. J Autism Dev Disord. 2003;33:607-16.
25. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1:54-77.
26. Careaga M, Rogers S, Hansen RL, Amaral DG, Van de Water J, Ashwood P. Immune endophenotypes in children with autism spectrum disorder. Biol Psychiatry. 2015 Sep 11. pii: S0006-3223(15) 00738-6. doi: 10.1016/j.biopsych.2015.08.036. [Epub ahead of print].
27. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res. 2007;85:1373-80.
28. Falcone T, Janigro D, Lovell R, Simon B, Brown CA, Herrera M, et al. S100B blood levels and childhood trauma in adolescent inpatients. J Psychiatr Res. 2015;62:14-22.
29. Villarreal A, Aviles Reyes RX, Angelo MF, Reines AG, Ramos AJ. S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-kappaB signaling. J Neurochem. 2011;117:321-32.
30. Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem. 2011;286:7214-26.
31. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia. 2001;33:131-42.
32. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280-8.
33. Young AM, Campbell EC, Lynch S, Dunn MH, Powis SJ, Suckling J. Regional susceptibility to TNF-alpha induction of murine brain inflammation via classical IKK/NF-kappaB signalling. PloS One. 2012;7:e39049.
34. O’Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997;20: 252-8.
35. Zurcher NR, Bhanot A, McDougle CJ, Hooker JM. A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: current state and future research opportunities. Neurosci Biobehav Rev. 2015;52:56-73.
36. Mukaddes NM, Herguner S, Tanidir C. Psychiatric disorders in individuals with high-functioning autism and Asperger’s disorder: similarities and differences. World J Biol Psychiatry. 2010;11:964-71.